Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

US regulators believe that Novo Nordisk’s new long-acting, once-a-day insulin, Tresiba, has a notable, but uncertain, cardiovascular risk. An initial assessment, based on a pooled analysis ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several ...

can buy Novo Nordisk’s insulin products for $35 per month for the next five years. The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its ...

A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi. “In 2018 ...

Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month. Under the settlement ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.

The agreement requires Denmark-based manufacturer Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month for the next five years, even for people without health insurance.

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...